Replies to post #137194 on Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

Do not compare K progress to anything else - it is worthless

With the speed K is progressing - it will be surprise if 1st patient enrolls in any P2 trial before Jun 1st

So investment in CTIX is more like lottery - specially the $1 range price - assume it is lost money - if you get something back - call yourself lucky.

[frrol]

K works on both active wt-p53 and mutant and upregulates the transcription-dependent and independent pathways, whereas the Aprea compound is for misfolded wt and mutant only.

One of the things that hit home reading "p53: The Gene That Cracked the Cancer Code" is that tumors are often not homogeneous; they contain cells with many different oncopathologies. If you address only one pathology and push the cancer into apparent remission, the cancer can come raging back, sadly, because the other untreated pathologies remain and those cancerous cells no longer have local competition for resources from the "defeated" cells. This is why cancer is perceived as so relentless a foe. And why combo-therapies are often necessary.

So Aprea's - or any other therapy's - success isn't a commercial challenge to Kevetrin; this is not a winner-take-all. What Kevetrin will be, if it is proven efficacious, is a safe general therapy for most cancer cases that can also be used in combo with everything. (I say "most" because it seems Kevetrin does not cross the blood-brain barrier unfortunately.)